This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Protagonist Therapeutics CEO Attends...
Business conference participation

Protagonist Therapeutics CEO Attends Conferences

Analysis based on 6 articles · First reported May 28, 2026 · Last updated May 28, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The participation of AnBogen Therapeutics in these conferences could positively impact its stock price by increasing investor awareness and confidence in its pipeline. Successful presentations by Dinesh V. Patel may lead to increased investment in AnBogen Therapeutics.

Biotechnology Pharmaceuticals
Event Summary

AnBogen Therapeutics announced that its President and CEO, Dinesh V. Patel, Ph.D., will participate in two investment bank conferences in June 2026: the 2026 Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference 2026. These appearances will feature fireside chats, offering an opportunity for AnBogen Therapeutics to highlight its proprietary technology platform and pipeline of peptide therapeutics. Key products include ICOTYDE, licensed to Johnson & Johnson — Janssen Pharmaceuticals, Inc. (a Johnson & Johnson company) and recently launched in the U.S. for plaque psoriasis, and rusfertide, licensed to Takeda Pharmaceutical Company and currently under priority review with the United States — Food and Drug Administration for polycythemia vera. The company also has several other clinical and preclinical programs.

Entities Involved
priv
AnBogen Therapeutics
AnBogen Therapeutics will participate in two investment bank conferences, providing an opportunity to present its pipeline and potentially attract investor interest.
Importance 100.0 Sentiment 10.0
per
Dinesh V. Patel
Dinesh V. Patel, CEO of AnBogen Therapeutics, will represent the company at the conferences, leading the fireside chats.
Importance 70.0 Sentiment 10.0
subs
Johnson & Johnson — Janssen Pharmaceuticals
Johnson & Johnson — Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, is responsible for the further development and commercialization of ICOTYDE.
Importance 30.0 Sentiment 0.0
stock
Johnson & Johnson
Johnson & Johnson, through its subsidiary Johnson & Johnson — Janssen Pharmaceuticals, Inc., is a licensee of ICOTYDE, a drug jointly discovered with AnBogen Therapeutics.
Importance 30.0 Sentiment 0.0
stock
Takeda Pharmaceutical Company
Takeda Pharmaceutical Company is the licensee for rusfertide, another peptide discovered by AnBogen Therapeutics.
Importance 30.0 Sentiment 0.0
stock
Goldman Sachs
Goldman Sachs is hosting one of the investment bank conferences where AnBogen Therapeutics will present.
Importance 20.0 Sentiment 0.0
stock
Mizuho Financial Group
Mizuho Financial Group is hosting one of the investment bank conferences where AnBogen Therapeutics will present.
Importance 20.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration is currently reviewing the New Drug Application for rusfertide.
Importance 10.0 Sentiment 0.0
Relationships
Johnson & Johnson related ↔ United States — Food and Drug Administration
Takeda Pharmaceutical Company related ↔ United States — Food and Drug Administration
Goldman Sachs related ↔ Mizuho Financial Group
Goldman Sachs related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.